Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04305184 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT04305184 is a Phase 1 study that was terminated before completion, run by Astellas Pharma Global Development. The registered enrollment target is 36 participants.
The verdict
NCT04305184, a Phase 1 study, was terminated before completion, sponsored by Astellas Pharma Global Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary purpose of this study was to evaluate the safety and tolerability of ASP0598 Otic Solution. This study also evaluated the efficacy of ASP0598 otic solution.
Interventions
- OTHER Placebo
- DRUG ASP0598
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2023-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04305184
The ClinicalTrials.gov registry entry for NCT04305184 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04305184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04305184 about?
NCT04305184 is a clinical study titled "A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)". The primary purpose of this study was to evaluate the safety and tolerability of ASP0598 Otic Solution. This study also evaluated the efficacy of ASP0598 otic solution.
What is the current status of trial NCT04305184?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2020-09-10. Estimated completion is 2023-01-24.
What interventions are being tested in trial NCT04305184?
The interventions under investigation include: Placebo (OTHER), ASP0598 (DRUG).
Who is sponsoring clinical trial NCT04305184?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.